Full-Time

Director Program

Clinical Data Management

Ipsen Global

Ipsen Global

5,001-10,000 employees

Global biopharma focused on specialty care

No salary listed

London, UK + 1 more

More locations: Paris, France

Hybrid

Category
Data & Analytics (1)
Requirements
  • Ability to manage data management large projects: plan activities and tasks, identify project constraints and dependencies, identify and mitigate risks, report on project status, produce progress metrics, and communicate efficiently with external vendors as well as internal partners
  • To perform any other activity as may reasonably required by Head of Data Management from time to time
  • Ability to produce high quality, accurate work to meet deadlines
  • Ability to interact satisfactorily with staff of differing disciplines
  • Well-developed time management, communication, presentation, analytical and interpersonal skills
  • Responsible, flexible and accountable with a pro-active approach
  • Ability to perform technical tasks and good understanding of clinical database structures and models
  • Understand the basic needs of statistics and programming
  • High level of expertise in the use of the data-management software
  • Approximately 8-15 years of experience in a similar position with proven Project Management skills in Data-Management activities at a development program level
  • Life Science and/or Information Technology graduate
  • English language proficiency
Responsibilities
  • Organize and coordinate the Data Management activities of an Asset including program level and study level from clinical synopsis / protocol review to the clinical study report and up to clinical data submission when applicable
  • Follow Asset Data-Management related budget and resources for the whole program including planning and re-evaluating needs on regular basis and reporting to the Head of Function in view of management at function level
  • Manage the budget aspect and potential change orders in relation with finance and Head of Function for the related Data-Management activities including planning, commitment, purchase order, receipt of goods, closing
  • Define and put in place a high quality, timely and robust data management strategy for the project (e.g. data capture tool, data delivery flow for submissions). Develop and implement project specific guidelines and support documentation
  • Provide Data Management input and expertise to the Asset Team throughout the clinical development. Ensure that the Data Management activities related to collection, processing and data transfers to the Ipsen data warehouse are conducted in compliance with best practices
  • Lead to selection of external vendors by evaluating their ability to deliver in the context of Ipsen projects
  • Oversee the external vendor’s activities and deliverables and report on the status of Data Management tasks as needed to the Study Team and/or Clinical Project Team. Make sure that subcontracted activities are delivered in line with the project expectations (timelines, quality and budget). Follows budget and potential change orders in relation with the Clinical Development Programs Department
  • Ensure compliance of the data management deliverables with Ipsen rules and standards (e.g. standard database within Ipsen data warehouse) and ensure that the requirements from the clinical study protocol and the statistical analysis are fulfilled
  • Monitor the data quality, completeness and trend between subgroups (e.g. between countries, centres…) at different pre-identified and agreed time point in a project corresponding to milestone such as data review, DSMC, interim analysis using tools such as those developed for risk based monitoring
  • Coordinate all necessary activities to reach in a timely manner the database lock milestone such as making sure that the last transfer is complete (included all external data, randomization data, coding, SAE reconciliation is complete). Approve the DB lock as Sponsor
  • To actively contribute as data expert in the submission team
  • The position includes functional management as well as hierarchical management
  • He/She manages the functional activities of the team members allocated to the projects.
  • He/She collaborates with team members to drive strategic project decision-making and deliver on commitments to the organization.
  • For hierarchical management: he/she is an effective team leader. Responsible for the recruitment, the talent development, provides line management and supervision of team members in his/her team including objectives definition, appraisal review...
  • The individual is responsible for building capabilities and technical skills within his/her group to ensure effective high-quality delivery.
  • Participate and/or Lead implementation of data quality systems and procedures and identify any needs for improvement.
  • Perform new technologies intelligence and adapt to them as appropriate. Participate in the continuous improvement of the Data Management system in Ipsen.
  • act as a SME, main point of contact for due diligence activities and risk assessments with specific emphasis on the data management and data quality aspects for new acquisitions, including leading the in-licensing agreements and new partner relationships.
  • To analyse and recommend solutions to the head of Data Management, Systems and Standards and any other Head of department within CDO and R&D on the organisation and participation in effective clinical trials programs.
  • To provide expertise as required as a contributing as author in the development of department SOPs, Working Procedures etc…
  • Review and approve key clinical documents CSR, dry Run etc…
  • Participate and contribute along with procurement to SP selection & oversight meeting.
  • Conduct activities in accordance with rules and values of IPSEN.
  • Within its sphere of activity, to respect the regulation, to apply the IPSEN good practices and standards, and the SHE procedures set up on the site.
  • Participate at the SHE training, proposed in the framework of the training at post of work.
  • Contribute to reduce the environmental impact of the activities on the site.
  • Inform his / her superiors of any changes affecting the post of work, so that the single document evaluation of occupational risks, can be updated, as well as any useful information to better take into account the EHS on site
  • Safeguards data integrity and patient safety. Ensures decisions and data strategies support ethical conduct, regulatory reliability, and inspection readiness. Promotes a consistent quality and compliance culture across internal teams and vendors.
  • Connects study execution to asset and submission strategy. Anticipates risks affecting timelines, standards, and data flow, and implements mitigation plans. Uses metrics and trend analysis to improve data quality, efficiency, and processes, while introducing appropriate innovation and technology.
  • Collaborates effectively across Clinical Operations, Biostatistics, Programming, Regulatory, and external partners. Influences in a matrix environment, manages challenging discussions constructively, and adapts communication to technical and non-technical stakeholders.
  • Leads, coaches, and develops Data Management staff. Sets clear expectations, provides feedback, and builds team capability in standards, quality oversight, and vendor management. Encourages ownership, learning, and knowledge sharing.
  • Operates effectively in ambiguity and changing development environments. Communicates decisions clearly, explains trade-offs, and escalates risks when needed. Maintains focus and resilience under delivery pressure.
  • Delivers reliable, inspection-ready databases on time and within budget. Holds teams and vendors accountable to performance standards. Drives continuous improvement and contributes clear, data-based recommendations to program and submission decisions.
Desired Qualifications
  • High knowledge of international standards (ICH, GCP, CDISC …) and regulations related to clinical studies, electronic data capture and data management
  • Experience of managing and developing relationships with Service Providers
  • Experience of working with multidisciplinary groups and ability to work within a team environment.
  • A good understanding of the drug development process
  • Good budget management understanding
  • Excellent organizational and management skills
  • Excellent verbal and written communication skills.

Ipsen is a global biopharmaceutical company that concentrates on specialty care, developing and marketing medicines for oncology, neuroscience, and rare diseases. Its products work by treating specific high-need conditions, ranging from historical diarrhea treatment Smecta to modern targeted therapies in cancer and neurological disorders. The company differentiates itself through a focused portfolio in niche therapeutic areas, growth via strategic acquisitions, and a long-standing family heritage that shaped its international expansion and IPO-driven capital for expansion. Its goal is to address unmet medical needs worldwide by providing effective therapies for patients with serious or rare conditions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boulogne-Billancourt, France

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • IPN01203 T cell activator advances in Phase I/II targeting Vβ6/Vβ10 for solid tumors.
  • IPN60300 ADC targets novel ITGA2 antigen overexpressed in pancreatic and gastric cancers.
  • ImCheck Therapeutics acquisition valued up to EUR 1 billion bolsters immuno-oncology pipeline.

What critics are saying

  • ImCheck EUR 1 billion acquisition overextends balance sheet post €500M bond in March 2025.
  • IPN01203 Phase I/II trials fail anti-tumor activity in pancreatic cancer within 12 months.
  • Merck KGaA captures Ojemda market share in pediatric glioma within 18 months.

What makes Ipsen Global unique

  • Ipsen focuses exclusively on oncology, rare diseases, and neuroscience therapeutic areas.
  • Mid-sized agility enables rapid commercialization in 88 countries with 5,000 employees.
  • Ojemda gains EU approval as first targeted therapy for pediatric low-grade glioma in 2026.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Ipsen Global who can refer or advise you

Benefits

Wellness Program

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Company News

MarketScreener
Apr 7th, 2026
Beech Tree wins AMF waiver exempting it from mandatory takeover bid for 26% Ipsen stake

French pharmaceutical company Ipsen has announced that Beech Tree, which holds a 26.03% stake in the company's capital and 33.05% of voting rights, has received a waiver from the French Financial Markets Authority exempting it from filing a mandatory public tender offer. The waiver follows the transfer of Henri Beaufour's stake in Beech Tree to the Alasol Foundation. The transaction includes a governance agreement between Altawin, the Alasol Foundation and Beech Tree. Under the agreement, the Alasol Foundation has committed to holding its Beech Tree shares for at least 15 years and will not interfere in Beech Tree's management of its Ipsen stake. The agreement also establishes Altawin's veto rights and ensures continuity with the strategic direction set during Beaufour's lifetime.

Chinook Observer
Mar 18th, 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR.

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR. GlobeNewswire | Ipsen Pharma Yesterday at 11:00pm PDT * IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors * ITGA2 revealed as novel target of Ipsen's investigational antibody drug conjugate IPN60300, over-expressed across numerous solid tumor types * Preclinical data show potential of Ipsen's growing collection of investigational medicines, leveraging precision immuno-modulation to deliver differentiated anti-tumor activity PARIS, FRANCE, 18 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vβ6/Vβ10 T cells. These latest preclinical data will expand the growing evidence base, reinforcing the first-in-class potential of IPN01203 to improve outcomes where there are significant unmet needs for people living with solid tumors. Additionally, Ipsen revealed ITGA2 as the novel target for innovative antibody-drug conjugate (ADC) IPN60300, now in active Phase I evaluation. Preclinical findings showed pronounced over-expression of ITGA2 across multiple solid tumors - including pancreatic, gastric and colorectal cancers - with clear differential expression when compared to normal tissues. These results confirmed that IPN60300 binds specifically and with high affinity to ITGA2, enabling efficient internalization and accumulation of the exatecan payload. Further preclinical tumor model data showed dose-dependent anti-tumor activity and favorable tolerability, suggesting a promising first-in-class therapy with the potential to improve clinical outcomes. "These data presented at AACR exemplify our approach to early science, showcasing how we are harnessing precision immuno-modulation backed by the strength of preclinical data to advance next generation therapies where there are the highest unmet needs," said Mary Jane Hinrichs, SVP Early Development, Ipsen. "It's a privilege to see the growing transformative potential of these new modalities, paving the way for potential best- and first-in-class impact for people living with cancer." Underscoring the strength and promise of Ipsen's precision medicine approach, IPN01203 and IPN60300 combine precision targeting with innovative mechanisms of action with the aim of delivering strength of efficacy where few other treatments exist. About IPN01203 IPN01203 is a first-in-class T cell activator which selectively activates a group of Vβ6 T cells through the TCR and IL-15R pathways, enhancing their ability to recognize and target tumors. IPN01203 was generated by Marengo's Selective T Cell Activation Repertoire (STAR) platform, a multi-specific fusion protein library that targets specific TCR Vβ variants fused to different co-stimulate moieties to develop potent T cell activators. A Phase I/II dose escalation and expansion trial is ongoing. About IPN60300 IPN60300 is a first-in-class antibody-drug conjugate targeting the novel tumor antigen ITGA2 known to be overexpressed in many solid tumors, including pancreatic, gastric and colorectal cancers. This novel tumor antigen was identified using Foreseen' Biotechnology's high throughput, integrated translational proteomics, and artificial intelligence (AI)-powered screening platforms. Comprised of an ITGA2-targeting antibody, exatecan payload and innovative linker from Escugen Biotechnology's EZWi-Fit(TM), IPN60300 is optimally designed to allow for a wide therapeutic index, with potential for improved efficacy over standard of care as well as a favorable safety profile. A Phase I/II dose escalation and expansion trial is ongoing. About Ipsen Chinook Observer is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Its pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Its teams in more than 40 countries and its partnerships around the world enable Chinook Observer to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. | Ipsen Contacts | / | / | | Investors | / | / | | Henry Wheeler | [email protected] | +33 7 66 47 11 49 | | Khalid Deojee | [email protected] | +33 6 66 01 95 26 | | Media | / | / | | Sally Bain | [email protected] | +1 857 320 0517 | | Anne Liontas | [email protected] | +33 7 67 34 72 96 | | / | / | / | Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipsen.com. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

EQT Group
Oct 22nd, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

· Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck’s shareholders will be eligible to receive a payment of EUR 350 million and downstream payments,  for a total potential consideration of up to EUR 1 billion. · ImCheck Therapeutics is a private French biotechnology company pioneering next-generation immuno-oncology therapies. · EQT Life Sciences has backed ImCheck since 2017 and has provided comprehensive support beyond capital, at the board level.

GlobeNewswire
Mar 19th, 2025
Ipsen announces issuance of €500 million inaugural Rated Public Bond

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a...

Business Wire
Jun 9th, 2023
BAKX Raises $25 Million to Develop Therapeutics Targeting Pro-Apoptotic Proteins and Mitochondrial Apoptosis Pathway

BAKX Therapeutics today announced it closed $25 million in a Series A fundraising led by AB Magnitude Ventures Group with Ipsen Pharma SA and Sherpa H